The impacts of social media algorithms are manifold: Algorithmically powered newsfeeds on social media threaten to destabilize countries and governments around the world, deeply impact mental health, ...

Democracy Now! speaks with science fiction author, activist and journalist Cory Doctorow about AI and his latest book, The Reverse Centaur’s Guide to Life After AI: How to Think About Artificial ...

Iran’s initial peace deal with the US sets the stage for Tehran to bolster Hezbollah’s financial and political grip in Lebanon once cash begins to flow from unfrozen funds and oil deals, according to ...

The most comprehensive independent study of AI-powered hiring algorithms ever conducted has found stark racial disparities embedded in the tools used to screen millions of job applicants, with more ...

Abstract: Nowadays, many two-sided platforms are actively launching new services beyond their main service to reach a broader range of consumers (e.g., A map adding local lifestyle services in ...

Ritholtz Wealth Management, a national RIA with $7.6 billion in AUM, launched its first equity-only SMA in partnership with Franklin Templeton. Called Porterhouse, the SMA is an actively-managed ...

It’s hard to ignore the seismic shifts brought about by algorithm-driven content. Every time you scroll through your social media feed or check your favorite news app, algorithms are diligently at ...

Personalized algorithms may quietly sabotage how people learn, nudging them into narrow tunnels of information even when they start with zero prior knowledge. In the study, participants using ...

For a year and a half, Yves Valerus was working a stable, full time job with a regular weekly schedule, a set hourly rate and benefits. The Haitian Creole-English interpreter helps people bridge ...

Lets geek out. The HackerNoon library is now ranked by reading time created. Start learning by what others read most. Lets geek out. The HackerNoon library is now ranked by reading time created. Start ...

After Spinraza's FDA approval nearly a decade ago, Biogen's spinal muscular atrophy (SMA) drug captured rapid momentum and delivered blockbuster-level sales in just its second year on the market.